Author: admin

  • Nicholas Brown – 2016 Parliamentary Question to the Department of Health

    Nicholas Brown – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Nicholas Brown on 2016-05-26.

    To ask the Secretary of State for Health, for what reasons the Lutathera drug was removed from the list of drugs available under the Cancer Drugs Fund.

    George Freeman

    Peptide receptor radionuclide therapy (including Luththera) for the treatment of gastro-entero-pancreatic neuroendocrine tumours was removed from the Cancer Drugs Fund in November 2015 on the grounds that it represented insufficient value for retention within the Fund.

    NHS England’s full decision summary is available at:

    https://www.england.nhs.uk/ourwork/cancer/cdf/cdf-drug-sum/

    “

  • Nicholas Brown – 2016 Parliamentary Question to the Department of Health

    Nicholas Brown – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Nicholas Brown on 2016-05-26.

    To ask the Secretary of State for Health, with reference to findings presented at the 2015 European Cancer Congress on Lutathera, what assessment he has made of the reported benefits of that drug on treating patients with neuroendocrine tumours.

    George Freeman

    The clinical research findings on Lutathera, presented to the European Cancer Congress, have not yet been published in a peer-reviewed journal.

    The National Institute for Health and Care Excellence (NICE) has been asked to develop technology appraisal guidance on lutetium-177 dotatate for the treatment of unresectable, somatostatin receptor-positive, gastroenteropancreatic neuroendocrine tumours. NICE’s guidance is based on a thorough assessment of the available evidence and is developed through wide consultation with stakeholders.

  • Dan Jarvis – 2016 Parliamentary Question to the Department of Health

    Dan Jarvis – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Dan Jarvis on 2016-05-26.

    To ask the Secretary of State for Health, what assessment his Department has made of the financial effect on people caring for family members of the closure of the Independent Living Fund and the introduction of the Care Act 2014.

    Alistair Burt

    The Independent Living Fund (ILF) closed on 30 June 2015, with funding and responsibility transferring to local authorities in England and the Devolved Administrations in Scotland and Wales. The Department has not made an assessment of the financial impact on those caring for family members, and at this stage does not plan to do so.

    However, the Department has issued statutory guidance to local authorities to support this transfer of responsibility and to prevent any former ILF user having their care interrupted during the transfer. I have recently reminded local authorities of the need to comply with this guidance. In addition, the Care Act 2014 introduced important new rights for carers, and placed a duty on local authorities to assess adults who appear to have care and support needs and to meet those needs which meet the national eligibility criteria.

    The Government has committed to publishing a new cross-Government National Carers Strategy before the end of 2016. A wide-ranging call for evidence is now underway to underpin the development of the Strategy, which will gather evidence from stakeholders, and carers themselves, on their experience of caring including issues of personal finance and the support they receive from local authorities.

  • William Wragg – 2016 Parliamentary Question to the Department of Health

    William Wragg – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by William Wragg on 2016-05-26.

    To ask the Secretary of State for Health, what assessment he made of the utility of data from the clinic in Brent and Harrow which has been providing men who have sex with men with HPV vaccinations since 2012 when determining that it was necessary to conduct an HPV vaccination pilot before deciding on a national roll-out; and if he will make a statement.

    Jane Ellison

    Experience from the two Brent and Harrow clinics providing human papillomavirus vaccinations to men who have sex with men was shared with Public Health England and has helped to inform the development of the pilot. North West London is unlikely to be representative of England as a whole and the pilot will therefore let us consider provision of this vaccination programme in different geographical areas. It will also consider a wider age range than the service provided in these two clinics. The pilot will cover men up to 45 years of age in line with advice from the Joint Committee on Vaccination and Immunisation (JCVI). The pilot will help resolve a range of implementation issues and determine whether a national programme can be delivered through Genito-Urinary Medicine and HIV clinics at a cost effective price in line with the JCVI’s advice.

  • Nicholas Soames – 2016 Parliamentary Question to the Department of Health

    Nicholas Soames – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Nicholas Soames on 2016-05-26.

    To ask the Secretary of State for Health, what change there was in the level of emergency admissions of older people between 2010-11 and 2014-15 in the Brighton and Sussex University Hospitals NHS Trust.

    Ben Gummer

    Between 2010-11 and 2014-15, there was a 5.4% increase in the number of emergency admissions of patients aged 65 and over at Brighton and Sussex University Hospitals NHS Trust.

  • Nicholas Brown – 2016 Parliamentary Question to the Department of Health

    Nicholas Brown – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Nicholas Brown on 2016-05-26.

    To ask the Secretary of State for Health, what assessment his Department has made of the adequacy of treatment and provision of support through the NHS for patients of neuroendocrine cancer.

    Jane Ellison

    NHS England has made an assessment of the need for national treatment decisions as to the commissioning of systemic therapies for neuroendocrine carcinomas. Based on this assessment, it has discussed the issue with the National Institute for Health and Care Excellence (NICE) and NICE has agreed to do a multiple technology appraisal of lanreotide, sunitinib, everolimus and peptide receptor radionuclide therapy. NICE guidance on these treatments is due in the summer of 2017. In the meantime, sunitinib is available from the Cancer Drugs Fund and lanreotide is available through routine commissioning.

  • Nicholas Brown – 2016 Parliamentary Question to the Department of Health

    Nicholas Brown – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Nicholas Brown on 2016-05-26.

    To ask the Secretary of State for Health, for what reasons the budget for the revised Cancer Drugs Fund was established at £340 million.

    George Freeman

    NHS England has advised that the Cancer Drugs Fund budget was increased to £340 million for 2015-16 and, with the new financial control and commercial mechanisms being put in place from 1 July 2016 under the new arrangements for the Fund, that budget increase will be maintained at £340 million for 2016-17.

  • Victoria Borwick – 2016 Parliamentary Question to the Department of Health

    Victoria Borwick – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Victoria Borwick on 2016-05-26.

    To ask the Secretary of State for Health, what research the Advisory Committee on the Safety of Blood, Tissues and Organs plans to undertake or commission on the risk of blood-borne viruses for former sex workers and ex-intravenous drug users.

    Jane Ellison

    As a Departmental Expert Committee the Advisory Committee on the Safety of Blood Tissues and Organs (SaBTO) does not undertake or commission research directly. SaBTO is carrying out a review of selection criteria for donation of blood, tissues and cells. The review will be wide-ranging and comprehensive and will include evidence relating to the risks of blood-borne infections in people who have previously injected drugs or received money or drugs for sex. Should any gaps be identified in the course of the review, SaBTO could make research recommendations.

  • Michelle Donelan – 2016 Parliamentary Question to the Department of Health

    Michelle Donelan – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Michelle Donelan on 2016-05-26.

    To ask the Secretary of State for Health, whether it is planned that the Government’s childhood obesity strategy will include targets for industry to reduce levels of (a) fat and (b) salt in food and drink.

    Jane Ellison

    Our Childhood Obesity Strategy, which will be launched in the summer, will look at everything that contributes to a child becoming overweight and obese. It will set out what more can be done by all.

  • Kerry McCarthy – 2016 Parliamentary Question to the Department of Health

    Kerry McCarthy – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Kerry McCarthy on 2016-05-26.

    To ask the Secretary of State for Health, how many children under the age of 18 in England have cystic fibrosis.

    Jane Ellison

    The Department has made no such assessment. The families of children with cystic fibrosis may be eligible for social care support, continuing care in the home, and Disability Living Allowance or Personal Independence Payments, based on the level of the child or young person’s needs.

    The number of children under the age of 18 with cystic fibrosis is not collected centrally. It is estimated that one in every 2,500 babies born in England has cystic fibrosis.